Hemab Therapeutics Holdings, INC

Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.

Hemab Therapeutics Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in R&D, progress in clinical trials for sutacimig and HMB-002, and a substantial cash position post-IPO.

Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have collectively reported beneficial ownership of 7.06% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Capital International Investors has disclosed beneficial ownership of 3,603,876 shares, representing 7.7% of Hemab Therapeutics Holdings, Inc.'s common stock.

Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock, collectively holding 5.1% of the outstanding shares.

Sofinnova Crossover II SLP and associated entities have reported beneficial ownership of 5.4% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.